Rare Neurological Disease Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028

Published on : Mar-2020 | List of Tables : 104 | List of Figures : 149 | No. of Pages : 170 | Report Code : FACT4594MR |

Shift towards Orphan Drugs is anticipated to Drive Demand Growth in Rare Neurological Disease Treatment Market

The global rare neurological disease treatment market is projected to expand at a stellar CAGR of over 8.5% and is anticipated to grow 2.3x between 2018 and 2028. Over the last decade, the prevalence of rare diseases, evolving trend of orphan drugs and increasing expenditure on healthcare has provided a huge momentum to overall sales of rare neurological drugs. As a result, the global sales within the rare neurological disorder treatment market has achieved a new milestone and surpassed the valuation of US$ 6.5 Bn in 2019. In addition, due to their relatively high market value share and growth rate, the rare neurological disease treatment market is estimated to remain the most lucrative market within the rare disease treatment markets. Furthermore, rapid developments in healthcare and dramatic socioeconomic changes resulting in modified lifestyles is also giving opportunities to manufacturers to expand their footprint within the rare neurological disease treatment market

 Revenue Share in Injectable Segment is forecast to Jump ~180 BPS

Ongoing research and development activities in the field of rare neurological disease treatment are proliferating on the back of increasing demand for orphan drugs. This is anticipated to create an absolute dollar opportunity of US$ 8.1 Bn between 2018 and 2028. The promulgation of disposable injectors is rapidly covering all aspects of the rare neurological disease treatment market. Hence, injectable drug delivery devices are acquiring a leading position. Furthermore, increasing demand for patient friendly parenteral drug delivery systems and increasing number of surgical treatments are expected to boost the growth of injectable segment over the forecast period.

rare neurological disease treatment market 02

Access our intuitive market intelligence on the neurological disease treatment market, request for a report sample here

Biologics Segment to Account for over 40% Market Share in Drug Class Category

A biopharmaceutical revolution is showing its prevalence in pharmaceutical research and development laboratories which is driving industry-wide progress, including the advancement of primary packaging and delivery technologies. Biologics is enabling the treatment of cancers, chronic autoimmune and lifestyle diseases that were previously untreatable. The biologics segment is projected to expand at a CAGR of over 7.5% over the long term forecast period (2018-2028). The key players in the biologics segments are likely to face less competition across the globe on back of the high level of complexity that is associated with the production of biologics

Asia-Pacific to Pave Way for Profitable Alliances for Key Manufacturers

North America is poised to be the leading region in the global rare neurological disease treatment market accounting for a 2/5th market share in 2019 on the back of well-established healthcare infrastructure and continuous emphasis on R&D in drugs and treatment of rare diseases. Changing regional demographics, epidemiology and amplified healthcare coverage plans in regions such as South Asia, East Asia and Latin America are propelling the global rare neurological disease treatment market within these regions. In Europe, the disease treatment industry is mainly bound to various government policies and market strategies. In a bid to attain a competitive edge over the market players at the global platforms, the players in Europe are concentrating on offering product innovations.

rare neurological disease treatment market 01

To get an exhaustive regional analysis on the neurological disease treatment market, ask an analyst here

Innovations in Value Chain is Setting a New Growth Trajectory for Key Market Actors

The global rare neurological disease treatment market is expected to showcase a consolidated market structure. Key industry giants such as Novartis AG, Pfizer Inc., and Johnson & Johnson Services, Inc. hold more than 50% of share in the global rare neurological disease treatment market and are anticipated to attract more end users in near future owing to its brand positioning across the globe. Manufacturers are focused on developing new therapies to decrease the burden of rare diseases, thus increasing their respective market shares. In addition, innovations across the value chain and drug delivery models is likely to play a vital role in order to gain more penetration in the global market.

Global Rare Neurological Disease Treatment Market – Scope of the Report

The following report provides forecast and analysis of the global rare neurological disease treatment market along with the historical data of 2013, estimated data 2018 and forecast data up to 2028 in terms of value (US$ Mn), according to a Fact.MR study. The research propounds critical trends that are currently influencing growth within the global rare neurological disease treatment market along with several macro-economic indicators. This newly published and insightful report on rare neurological disease treatment sheds light on key dynamics, and their impact on the overall value chain from suppliers to end-users, which are expected to transform the future of the global rare neurological disease treatment market.

The report also comprises the study of current issues with end users and opportunities for rare neurological disease treatment. It also contains value chain analysis, including the key market participants. To provide users of this report with a comprehensive view of the market, we have included a detailed competitive analysis about the key players involved in the market and strategic overviews. The dashboard included in the report provides a detailed comparison of rare neurological disease treatment manufacturers on parameters such as total revenue, product offerings, and key strategies. A list of key companies operating in the rare neurological disease treatment market provided in the report adds to the credibility of this exhaustive research study.

Global Rare Neurological Disease Treatment Market: In-Depth Assessment on Key Segments

The global rare neurological disease treatment market is segmented on the basis of drug class, route of administration, disease indication, distribution channel, and region.

Drug Class

Route of Administration

Disease Indication

Distribution Channel

Region

Anti-depressants

Injectable

Alzheimer's Diseases

Hospital Pharmacies

North America

Anti-psychotics

Oral

Narcolepsy

Retail Pharmacies and Drug Store

Latin America

Cholinesterase Inhibitors

 

Multiple Sclerosis

Online Pharmacies

Europe

Biologics

 

Amyotrophic Lateral Sclerosis

 

South Asia

Others (Anti-vertigo, Anti-seizure, etc.)

 

Others

 

East Asia

       

Oceania

       

Middle East & Africa

This taxonomy and the detailed TOC prepared are confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited. 

Country-specific assessment on demand for rare neurological disease treatment has been provided for each regional market, along with the market size valuation and forecast price point assessment, price index and impact analysis of key regional and country-wise dynamics, which were obtained through quotes from numerous rare neurological disease treatment manufacturers, experts, and suppliers. Y-o-Y growth projections have also been offered on all regional markets incorporated in the report. Moreover, future trends, growth prospects, and other possibilities related to the market have been answered in the report.

The report provides company-level market share analysis, which has been derived on the basis of the company’s annual sales and segmental revenue in all the target disease indications. The market has been forecasted based on constant currency rates. The report provides detailed competitive and company profiles of key participants operating in the global rare neurological disease treatment market. Some of the key competitors operating in the rare neurological disease treatment market are Novartis AG, Pfizer, Inc., Johnson & Johnson Services, Inc. Bayer AG, GlaxoSmithKline Plc, Sanofi S.A., Allergan Plc, Merck & Co., Inc., and others.

Global Rare Neurological Disease Treatment Market: Research Methodology

A number of primary and secondary sources were consulted during the course of the study. Secondary sources include Factiva, Morningstar and Hoovers, and company annual reports and publications. Comprehensive interviews have been conducted by our analysts, and the intelligence and insights obtained have been used for validating the information gained through secondary research. The report also includes a description of assumptions and acronyms utilized for research purposes. Data gathered has been validated using the triangulation method to offer useful quantitative and qualitative insights into the rare neurological disease treatment market.

A short market viewpoint offered in the report elucidates the macro-economic aspects that influence the growth of the rare neurological disease treatment market, which includes global GDP growth rate, healthcare industry growth rate, prevalence rate of rare diseases, per capita spending on healthcare, number of healthcare facilities by countries, etc. This report serves as an authentic resource of intelligence on the rare neurological disease treatment market, enabling the readers to take fact-based decisions on the future direction of their businesses.

1. Global Rare Neurological Disease Treatment Market - Executive Summary

    1.1. Summary of Key Findings

    1.2. Summary of Key Statistics

    1.3. Treatment Evolution

    1.4. Fact.MR Analysis and Recommendations

2. Global Rare Neurological Disease Treatment Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

        3.1.1. Standard Framework For Screening New-Born

        3.1.2. Interactive Course To Raise Awareness About Rare Diseases

        3.1.3. Patient Groups Are Playing An Active Role In Supporting Coordinated Care

        3.1.4. Shift Towards Orphan Drugs

        3.1.5. Others

4. Key Success Factors

    4.1. Product Adoption / Awareness Analysis 

    4.2. Product Features Vs. Application Matrix 

    4.3. Strategic Promotional Strategies, By Key Manufacturers

    4.4. Key Market Attributes & Characteristics

    4.5. Investment Feasibility Matrix

5. Global Rare Neurological Disease Treatment Pricing Point Analysis

    5.1. Regional Pricing Analysis By Drug Class 

    5.2. Pricing Break-up 

        5.2.1. Manufacturer Level Pricing 

        5.2.2. Distributor Level Pricing 

    5.3. Global Average Pricing Analysis Benchmark 

6. Global Rare Neurological Disease Market Demand (in Value US$ Mn) Analysis 2013-2017 and Forecast, 2018-2028 

    6.1. Historical Market Value (US$ Mn) Analysis, 2013-2017 

    6.2. Current and Future Market Value (US$ Mn) Projections, 2018-2028

7. Market Background 

    7.1. Global Rare Disease Treatment Market Outlook, 2018

        7.1.1. By Regions

        7.1.2. By Disease Indication

    7.2. Global Rare Disease Treatment Market Opportunity Assessment

    7.3. Regularity Framework by Regions/Key Countries

    7.4. Macro-Economic and Forecast Factors

        7.4.1. GDP Growth Outlook

        7.4.2. Rising per-Capita Healthcare Expenditure

        7.4.3. High Prevalence of Rare Neurological Disorders in Developing Countries

        7.4.4. Growing Awareness on Rare Neurological Diseases

        7.4.5. Increase In Investment on Healthcare Sector by The Pharmaceutical Companies

        7.4.6. Rise in Treatment Adoption Rate

        7.4.7. Enhanced R&D for Rare Neurological Diseases

        7.4.8. Others

    7.5. Value Chain Analysis

        7.5.1. List of Key Market Manufacturers 

        7.5.2. List of Key Channel Partners 

        7.5.3. Profitability Margins 

    7.6. Market Dynamics 

        7.6.1. Drivers 

        7.6.2. Industry Challenges

        7.6.3. Opportunities

8. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Drug Class 

    8.1. Introduction / Key Findings 

    8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013 - 2017 

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2018 - 2018 

        8.3.1. Anti-depressants

        8.3.2. Anti-psychotics

        8.3.3. Cholinesterase Inhibitors

        8.3.4. Biologics

        8.3.5. Others (Anti-vertigo, anti-seizure)

    8.4. Market Attractiveness Analysis By Drug Class

9. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration 

    9.1. Introduction / Key Findings 

    9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013 - 2017 

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2018 - 2018 

        9.3.1. Injectable 

        9.3.2. Oral 

    9.4. Market Attractiveness Analysis By Route of Administration 

10. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication 

    10.1. Introduction / Key Findings 

    10.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2013 - 2017 

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2018 - 2018 

        10.3.1. Alzheimer’s Disease 

        10.3.2. Narcolepsy 

        10.3.3. Multiple Sclerosis 

        10.3.4. Amyotrophic Lateral Sclerosis 

        10.3.5. Others 

    10.4. Market Attractiveness Analysis By Disease Indication 

11. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel 

    11.1. Introduction / Key Findings 

    11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013 - 2017 

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2018 - 2018 

        11.3.1. Hospitals Pharmacies 

        11.3.2. Retail Pharmacies & Drug Stores 

        11.3.3. Online Pharmacies 

    11.4. Market Attractiveness Analysis By Distribution Channel 

12. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Region 

    12.1. Introduction 

    12.2. Historical Market Size (US$ Mn) Analysis By Region, 2013 - 2017 

    12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2018 - 2018 

        12.3.1. North America 

        12.3.2. Latin America 

        12.3.3. Europe 

        12.3.4. South Asia 

        12.3.5. East Asia 

        12.3.6. Oceania 

        12.3.7. MEA

    12.4. Market Attractiveness Analysis By Region 

13. North America Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028

    13.1. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country

        13.1.1. US

        13.1.2. Canada

    13.2. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class

        13.2.1. Anti-depressants

        13.2.2. Anti-psychotics

        13.2.3. Cholinesterase Inhibitors

        13.2.4. Biologics

        13.2.5. Others (Anti-vertigo, anti-seizure)

    13.3. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration

        13.3.1. Injectable

        13.3.2. Oral

    13.4. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication

        13.4.1. Alzheimer’s Disease 

        13.4.2. Narcolepsy 

        13.4.3. Multiple Sclerosis 

        13.4.4. Amyotrophic Lateral Sclerosis 

        13.4.5. Others

    13.5. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel

        13.5.1. Hospitals Pharmacies 

        13.5.2. Retail Pharmacies & Drug Stores 

        13.5.3. Online Pharmacies

    13.6. Market Attractiveness Analysis 

        13.6.1. By Country 

        13.6.2. By Drug Class 

        13.6.3. By Route of Administration 

        13.6.4. By Disease Indication 

        13.6.5. By Distribution Channel 

    13.7. Market Trends 

    13.8. Key Market Participants - Intensity Mapping 

    13.9. Drivers and Restraints - Impact Analysis

14. Latin America Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028

    14.1. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country

        14.1.1. Brazil

        14.1.2. Mexico

        14.1.3. Rest of Latin America

    14.2. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class

        14.2.1. Anti-depressants

        14.2.2. Anti-psychotics

        14.2.3. Cholinesterase Inhibitors

        14.2.4. Biologics

        14.2.5. Others (Anti-vertigo, anti-seizure)

    14.3. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration

        14.3.1. Injectable

        14.3.2. Oral

    14.4. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication

        14.4.1. Alzheimer’s Disease 

        14.4.2. Narcolepsy 

        14.4.3. Multiple Sclerosis 

        14.4.4. Amyotrophic Lateral Sclerosis 

        14.4.5. Others

    14.5. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel

        14.5.1. Hospitals Pharmacies 

        14.5.2. Retail Pharmacies & Drug Stores 

        14.5.3. Online Pharmacies

    14.6. Market Attractiveness Analysis 

        14.6.1. By Country 

        14.6.2. By Drug Class 

        14.6.3. By Route of Administration 

        14.6.4. By Disease Indication 

        14.6.5. By Distribution Channel 

    14.7. Market Trends 

    14.8. Key Market Participants - Intensity Mapping 

    14.9. Drivers and Restraints - Impact Analysis

15. Europe Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028

    15.1. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country

        15.1.1. Germany

        15.1.2. France

        15.1.3. Italy

        15.1.4. Denmark

        15.1.5. UK

        15.1.6. Russia

        15.1.7. Spain

        15.1.8. Rest of Europe

    15.2. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class

        15.2.1. Anti-depressants

        15.2.2. Anti-psychotics

        15.2.3. Cholinesterase Inhibitors

        15.2.4. Biologics

        15.2.5. Others (Anti-vertigo, anti-seizure)

    15.3. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration

        15.3.1. Injectable

        15.3.2. Oral

    15.4. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication

        15.4.1. Alzheimer’s Disease 

        15.4.2. Narcolepsy 

        15.4.3. Multiple Sclerosis 

        15.4.4. Amyotrophic Lateral Sclerosis 

        15.4.5. Others

    15.5. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel

        15.5.1. Hospitals Pharmacies 

        15.5.2. Retail Pharmacies & Drug Stores 

        15.5.3. Online Pharmacies

    15.6. Market Attractiveness Analysis 

        15.6.1. By Country 

        15.6.2. By Drug Class 

        15.6.3. By Route of Administration 

        15.6.4. By Disease Indication 

        15.6.5. By Distribution Channel 

    15.7. Market Trends 

    15.8. Key Market Participants - Intensity Mapping 

    15.9. Drivers and Restraints - Impact Analysis

16. South Asia & Oceania Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028

    16.1. South Asia & Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country

        16.1.1. India

        16.1.2. Indonesia

        16.1.3. Thailand

        16.1.4. Malaysia

        16.1.5. Rest of South Asia

    16.2. South Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class

        16.2.1. Anti-depressants

        16.2.2. Anti-psychotics

        16.2.3. Cholinesterase Inhibitors

        16.2.4. Biologics

        16.2.5. Others (Anti-vertigo, anti-seizure)

    16.3. South Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration

        16.3.1. Injectable

        16.3.2. Oral

    16.4. South Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication

        16.4.1. Alzheimer’s Disease 

        16.4.2. Narcolepsy 

        16.4.3. Multiple Sclerosis 

        16.4.4. Amyotrophic Lateral Sclerosis 

        16.4.5. Others

    16.5. South Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel

        16.5.1. Hospitals Pharmacies 

        16.5.2. Retail Pharmacies & Drug Stores 

        16.5.3. Online Pharmacies

    16.6. Market Attractiveness Analysis 

        16.6.1. By Country 

        16.6.2. By Drug Class 

        16.6.3. By Route of Administration 

        16.6.4. By Disease Indication 

        16.6.5. By Distribution Channel 

    16.7. Market Trends 

    16.8. Key Market Participants - Intensity Mapping 

    16.9. Drivers and Restraints - Impact Analysis

17. East Asia Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028

    17.1. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country

        17.1.1. China

        17.1.2. Japan

        17.1.3. South Korea

    17.2. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class

        17.2.1. Anti-depressants

        17.2.2. Anti-psychotics

        17.2.3. Cholinesterase Inhibitors

        17.2.4. Biologics

        17.2.5. Others (Anti-vertigo, anti-seizure)

    17.3. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration

        17.3.1. Injectable

        17.3.2. Oral

    17.4. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication

        17.4.1. Alzheimer’s Disease 

        17.4.2. Narcolepsy 

        17.4.3. Multiple Sclerosis 

        17.4.4. Amyotrophic Lateral Sclerosis 

        17.4.5. Others

    17.5. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel

        17.5.1. Hospitals Pharmacies 

        17.5.2. Retail Pharmacies & Drug Stores 

        17.5.3. Online Pharmacies

    17.6. Market Attractiveness Analysis 

        17.6.1. By Country 

        17.6.2. By Drug Class 

        17.6.3. By Route of Administration 

        17.6.4. By Disease Indication 

        17.6.5. By Distribution Channel 

    17.7. Market Trends 

    17.8. Key Market Participants - Intensity Mapping 

    17.9. Drivers and Restraints - Impact Analysis

18. Oceania Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028

    18.1. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country

        18.1.1. Australia

        18.1.2. New Zealand

    18.2. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class

        18.2.1. Anti-depressants

        18.2.2. Anti-psychotics

        18.2.3. Cholinesterase Inhibitors

        18.2.4. Biologics

        18.2.5. Others (Anti-vertigo, anti-seizure)

    18.3. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration

        18.3.1. Injectable

        18.3.2. Oral

    18.4. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication

        18.4.1. Alzheimer’s Disease 

        18.4.2. Narcolepsy 

        18.4.3. Multiple Sclerosis 

        18.4.4. Amyotrophic Lateral Sclerosis 

        18.4.5. Others

    18.5. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel

        18.5.1. Hospitals Pharmacies 

        18.5.2. Retail Pharmacies & Drug Stores 

        18.5.3. Online Pharmacies

    18.6. Market Attractiveness Analysis 

        18.6.1. By Country 

        18.6.2. By Drug Class 

        18.6.3. By Route of Administration 

        18.6.4. By Disease Indication 

        18.6.5. By Distribution Channel 

    18.7. Market Trends 

    18.8. Key Market Participants - Intensity Mapping 

    18.9. Drivers and Restraints - Impact Analysis

19. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028

    19.1. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country

        19.1.1. GCC Countries

        19.1.2. Northern Africa

        19.1.3. South Africa

        19.1.4. Rest of MEA

    19.2. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class

        19.2.1. Anti-depressants

        19.2.2. Anti-psychotics

        19.2.3. Cholinesterase Inhibitors

        19.2.4. Biologics

        19.2.5. Others (Anti-vertigo, anti-seizure)

    19.3. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration

        19.3.1. Injectable

        19.3.2. Oral

    19.4. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication

        19.4.1. Alzheimer’s Disease 

        19.4.2. Narcolepsy 

        19.4.3. Multiple Sclerosis 

        19.4.4. Amyotrophic Lateral Sclerosis 

        19.4.5. Others

    19.5. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel

        19.5.1. Hospitals Pharmacies 

        19.5.2. Retail Pharmacies & Drug Stores 

        19.5.3. Online Pharmacies

    19.6. Market Attractiveness Analysis 

        19.6.1. By Country 

        19.6.2. By Drug Class 

        19.6.3. By Route of Administration 

        19.6.4. By Disease Indication 

        19.6.5. By Distribution Channel 

    19.7. Market Trends 

    19.8. Key Market Participants - Intensity Mapping 

    19.9. Drivers and Restraints - Impact Analysis

20. Global Rare Neurological Disease Treatment Market –Emerging Countries Analysis

    20.1. Introduction

        20.1.1. Market Proportion Analysis, By Key Countries

        20.1.2. Global Vs. Country Growth Comparison

    20.2. Brazil Rare Neurological Disease Market Analysis and Forecast

        20.2.1. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 

            20.2.1.1. By Drug Class 

            20.2.1.2. By Route of Administration 

            20.2.1.3. By Disease Indication 

            20.2.1.4. By Distribution Channel 

        20.2.2. Market Attractiveness Analysis 

            20.2.2.1. By Drug Class 

            20.2.2.2. By Route of Administration 

            20.2.2.3. By Disease Indication 

            20.2.2.4. By Distribution Channel 

    20.3. India Rare Neurological Disease Market Analysis and Forecast

        20.3.1. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 

            20.3.1.1. By Drug Class 

            20.3.1.2. By Route of Administration 

            20.3.1.3. By Disease Indication 

            20.3.1.4. By Distribution Channel 

        20.3.2. Market Attractiveness Analysis 

            20.3.2.1. By Drug Class 

            20.3.2.2. By Route of Administration 

            20.3.2.3. By Disease Indication 

            20.3.2.4. By Distribution Channel 

    20.4. China Rare Neurological Disease Market Analysis and Forecast

        20.4.1. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 

            20.4.1.1. By Drug Class 

            20.4.1.2. By Route of Administration 

            20.4.1.3. By Disease Indication 

            20.4.1.4. By Distribution Channel 

        20.4.2. Market Attractiveness Analysis 

            20.4.2.1. By Drug Class 

            20.4.2.2. By Route of Administration 

            20.4.2.3. By Disease Indication 

            20.4.2.4. By Distribution Channel 

21. Competitive Assessment

    21.1. Global Rare Neurological Disease Treatment Market Structure

    21.2. Global Rare Neurological Disease Treatment Market Competition - a Dashboard View

    21.3. Global Rare Neurological Disease Treatment Market Company Share Analysis

    21.4. Global Rare Neurological Disease Treatment Competitor Market Footprint Matrix

    21.5. Key Participants Market Presence (Intensity Mapping) by Region

22. Company Profiles

    22.1. Novartis AG

        22.1.1. Overview

        22.1.2. Product Portfolio

        22.1.3. Sales Footprint

        22.1.4. Key Financials

        22.1.5. Revenue Split by Segments (Product/Region)

        22.1.6. Strategy Overview

        22.1.7. SWOT Analysis

    22.2. Pfizer, Inc.

        22.2.1. Overview

        22.2.2. Product Portfolio

        22.2.3. Sales Footprint

        22.2.4. Key Financials

        22.2.5. Revenue Split by Segments (Product/Region)

        22.2.6. Strategy Overview

        22.2.7. SWOT Analysis

    22.3. Sanofi S.A.

        22.3.1. Overview

        22.3.2. Product Portfolio

        22.3.3. Sales Footprint

        22.3.4. Key Financials

        22.3.5. Revenue Split by Segments (Product/Region)

        22.3.6. Strategy Overview

        22.3.7. SWOT Analysis

    22.4. Bayer AG

        22.4.1. Overview

        22.4.2. Product Portfolio

        22.4.3. Sales Footprint

        22.4.4. Key Financials

        22.4.5. Revenue Split by Segments (Product/Region)

        22.4.6. Strategy Overview

        22.4.7. SWOT Analysis

    22.5. Merck & Co. Inc.

        22.5.1. Overview

        22.5.2. Product Portfolio

        22.5.3. Sales Footprint

        22.5.4. Key Financials

        22.5.5. Revenue Split by Segments (Product/Region)

        22.5.6. Strategy Overview

        22.5.7. SWOT Analysis

    22.6. Allergan Plc

        22.6.1. Overview

        22.6.2. Product Portfolio

        22.6.3. Sales Footprint

        22.6.4. Key Financials

        22.6.5. Revenue Split by Segments (Product/Region)

        22.6.6. Strategy Overview

        22.6.7. SWOT Analysis

    22.7. Johnson & Johnson Services, Inc.

        22.7.1. Overview

        22.7.2. Product Portfolio

        22.7.3. Sales Footprint

        22.7.4. Key Financials

        22.7.5. Revenue Split by Segments (Product/Region)

        22.7.6. Strategy Overview

        22.7.7. SWOT Analysis

    22.8. Abbott Laboratories

        22.8.1. Overview

        22.8.2. Product Portfolio

        22.8.3. Sales Footprint

        22.8.4. Key Financials

        22.8.5. Revenue Split by Segments (Product/Region)

        22.8.6. Strategy Overview

        22.8.7. SWOT Analysis

    22.9. GlaxoSmithKline Plc

        22.9.1. Overview

        22.9.2. Product Portfolio

        22.9.3. Sales Footprint

        22.9.4. Key Financials

        22.9.5. Revenue Split by Segments (Product/Region)

        22.9.6. Strategy Overview

        22.9.7. SWOT Analysis

    22.10. Teva Pharmaceutical Industries Ltd.

        22.10.1. Overview

        22.10.2. Product Portfolio

        22.10.3. Sales Footprint

        22.10.4. Key Financials

        22.10.5. Revenue Split by Segments (Product/Region)

        22.10.6. Strategy Overview

        22.10.7. SWOT Analysis

    22.11. Sun Pharmaceutical Industries Ltd

        22.11.1. Overview

        22.11.2. Product Portfolio

        22.11.3. Sales Footprint

        22.11.4. Key Financials

        22.11.5. Revenue Split by Segments (Product/Region)

        22.11.6. Strategy Overview

        22.11.7. SWOT Analysis

    22.12. Biogen, Inc.

        22.12.1. Overview

        22.12.2. Product Portfolio

        22.12.3. Sales Footprint

        22.12.4. Key Financials

        22.12.5. Revenue Split by Segments (Product/Region)

        22.12.6. Strategy Overview

        22.12.7. SWOT Analysis

    22.13. Eisai Co., Ltd.

        22.13.1. Overview

        22.13.2. Product Portfolio

        22.13.3. Sales Footprint

        22.13.4. Key Financials

        22.13.5. Revenue Split by Segments (Product/Region)

        22.13.6. Strategy Overview

        22.13.7. SWOT Analysis

    22.14. Acer Therapeutics, Inc. (Opexa)

        22.14.1. Overview

        22.14.2. Product Portfolio

        22.14.3. Sales Footprint

        22.14.4. Key Financials

        22.14.5. Revenue Split by Segments (Product/Region)

        22.14.6. Strategy Overview

        22.14.7. SWOT Analysis

    22.15. Wockhardt Limited

        22.15.1. Overview

        22.15.2. Product Portfolio

        22.15.3. Sales Footprint

        22.15.4. Key Financials

        22.15.5. Revenue Split by Segments (Product/Region)

        22.15.6. Strategy Overview

        22.15.7. SWOT Analysis

    22.16. AB Science

        22.16.1. Overview

        22.16.2. Product Portfolio

        22.16.3. Sales Footprint

        22.16.4. Key Financials

        22.16.5. Revenue Split by Segments (Product/Region)

        22.16.6. Strategy Overview

        22.16.7. SWOT Analysis

23. Fact.MR Research Methodology

24. Disclaimer & Contact Information

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Rare Neurological Disease Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028